Third, the extensive clinical use of roflumilast (in COPD settings [37]) confirms its excellent safety profile, suggesting that the well-described toxicity associated with SYK, BTK and PI3K inhibitors may be avoided if these enzymes are inhibited indirectly via the roflumilast-induced elevation of cAMP levels. This evidence concerns the gene BTK and chronic obstructive pulmonary disease.